BioCentury
ARTICLE | Company News

PanOptica, Astellas deal

January 10, 2011 8:00 AM UTC

Astellas' OSI Pharmaceuticals Inc. subsidiary granted PanOptica exclusive, worldwide rights to develop and commercialize PAN-90806 for ophthalmic indications. The small molecule selective inhibitor ...